{"id":6874,"date":"2013-05-28T05:33:14","date_gmt":"2013-05-28T09:33:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=6874"},"modified":"2013-05-28T05:33:14","modified_gmt":"2013-05-28T09:33:14","slug":"oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874","title":{"rendered":"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Oragenics Inc (NYSEMKT:OGEN) rose by 21.38%. It opened at $2.79 per share, touched an intraday high of $3.35 and dropped down to close at $2.74 per share. More than 0.227 million shares were traded in Friday\u2019s trading session. This number stood above the average volume of 0.128 million that was measured over a 30-day period.<\/p>\n<p style=\"text-align: justify;\">Oragenics Inc (NYSEMKT:OGEN) is highly focused on becoming the world-leader in\u00a0novel antibiotics. These are used to fight against infectious disease\u00a0and its probiotics are used for oral health for humans as well as pets. The company has established a very exclusive, global channel collaboration that is used for lantibiotics. This is a novel class of various broad spectrum antibiotics. It has a collaboration with a synthetic biology company, Intrexon Corporation Inc. This collaboration allows Oragenics Inc (NYSEMKT:OGEN) access to Intrexon Corporation Inc\u2019s proprietary technologies. The objective of the alliance is to accelerate the development of the much needed newer antibiotics. These are meant to work against various resistant bacteria strains.<\/p>\n<p style=\"text-align: justify;\">Oragenics Inc (NYSEMKT:OGEN) is also involved in developing, marketing and selling proprietary probiotics. These probiotics are designed specifically to improve oral health for humans as well as for pets. They are sold under the Evora and ProBiora brand names in more than 13 countries across the globe. The company\u2019s SMaRT Replacement Therapy is specially designed as a treatment that has to be applied directly to the teeth. It has the ability to protect against tooth decay or dental caries<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Oragenics Inc (NYSEMKT:OGEN) rose by 21.38%. It opened at $2.79 per share, touched an intraday high of [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":6875,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2299,2298],"stock_ticker":[],"class_list":["post-6874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysemktogen","tag-oragenics-inc-nysemktogen","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Oragenics Inc (NYSEMKT:OGEN) rose by 21.38%. It opened at $2.79 per share, touched an intraday high of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-05-28T09:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics\",\"datePublished\":\"2013-05-28T09:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\"},\"wordCount\":266,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg\",\"keywords\":[\"NYSEMKT:OGEN\",\"Oragenics Inc (NYSEMKT:OGEN)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\",\"name\":\"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg\",\"datePublished\":\"2013-05-28T09:33:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874","og_locale":"en_US","og_type":"article","og_title":"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics - Wall Street PR","og_description":"Boston, MA 05\/28\/2013 (wallstreetpr) &#8211;\u00a0In Friday\u2019s trading session, Oragenics Inc (NYSEMKT:OGEN) rose by 21.38%. It opened at $2.79 per share, touched an intraday high of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-05-28T09:33:14+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics","datePublished":"2013-05-28T09:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874"},"wordCount":266,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg","keywords":["NYSEMKT:OGEN","Oragenics Inc (NYSEMKT:OGEN)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874","url":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874","name":"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg","datePublished":"2013-05-28T09:33:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/3060243118_f22ac2d56a_b.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/oragenics-inc-nysemktogen-focus-to-be-the-world-leader-in-novel-antibiotics-6874#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Oragenics Inc (NYSEMKT:OGEN) focus to be the world-leader in novel antibiotics"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/6874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=6874"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/6874\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/6875"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=6874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=6874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=6874"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=6874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}